Current Cardiology Reports

, Volume 5, Issue 5, pp 358–363

Evolving concepts in the treatment of atrial fibrillation

  • Parimal B. Maniar
  • Jonathan S. Steinberg
Article

Abstract

Atrial fibrillation (AF) is common among older adults, and its prevalence is increasing due to an aging population. This article reviews the recent insights into the mechanisms of AF, new developments in pharmacologic and nonpharmacologic therapy, and the impact of recent randomized clinical trials in the management of AF. Randomized clinical trials have shown that rhythm control with antiarrhythmic drugs offers no advantage over rate control for the prevention of death and cardiovascular morbidity. Catheter ablation of AF may play an increasingly important role in the future.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Go AS, Hylek EM, Phillips KA, et al.: Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001, 285:2370–2375.PubMedCrossRefGoogle Scholar
  2. 2.
    Benjamin EJ, Levy D, Vaziri SM, et al.: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271:840–844.PubMedCrossRefGoogle Scholar
  3. 3.
    Kannel WB, Wolf PA, Benjamin EJ, et al.: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 2N–9N.Google Scholar
  4. 4.
    Wolf PA, Dawber TR, Thomas HE, et al.: Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology 1978, 28:973–977.PubMedGoogle Scholar
  5. 5.
    Wolf PA, Abbott RD, Kannel WB, et al.: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983–988.PubMedGoogle Scholar
  6. 6.
    Benjamin EJ, Wolf PA, D’Agostino RB, et al.: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946–952.PubMedGoogle Scholar
  7. 7.
    Jung W, Luderitz B: Quality of life in patients with atrial fibrillation. J Cardiovasc Electrophysiol 1998, 9(Suppl):S177-S186.PubMedCrossRefGoogle Scholar
  8. 8.
    Maglio C, Ayers G, Tidball EW, et al.: Health care utilization and cost of care in patients with symptomatic atrial fibrillation. Circulation 1996, 94(Suppl):1–169.Google Scholar
  9. 9.
    Hamer ME, Blumenthal JA, McCarthy EA, et al.: Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol 1994, 135:819–824.Google Scholar
  10. 10.
    Fuster V, Ryden LE, Asinger RW, et al.: ACC /AHA/ESC guidelines for the managment of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2001, 38:1231–1265. This article provides comprehensive, evidence-based practice guidelines for the management of patients with AF.PubMedCrossRefGoogle Scholar
  11. 11.
    Moe GK, Abildskov JA: Atrial fibrillation as a self sustaining arrhythmia independent of focal discharge. Am Heart J 1959, 58:59–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Moe GK, Abildskov JA: Observations on the ventricular dysrhythmia associated with atrial fibrillation in the dog heart. Circ Res 1964, 4:447–460.Google Scholar
  13. 13.
    Wijffels MC, Kirchhof CJ, Dorland R, et al.: Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: role of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997, 96:3710–3720.PubMedGoogle Scholar
  14. 14.
    Nattel S, Li D: Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000, 87:440–447.PubMedGoogle Scholar
  15. 15.
    Van der Velden HM, Ausma J, Rook MB, et al.: Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000, 46:476–486.PubMedCrossRefGoogle Scholar
  16. 16.
    Fareh S, Villemaire C, Nattel S: Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial remodeling. Circulation 1998, 98:2202–2209.PubMedGoogle Scholar
  17. 17.
    Wijffels MC, Kirchhof CJ, Dorland R, et al.: Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995, 92:1954–1968. This experimental study introduced the concept that AF begets AF.PubMedGoogle Scholar
  18. 18.
    Hobbs WJ, Fynn S, Todd DM, et al.: Reversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation in humans. Circulation 2000, 101:1145–51.PubMedGoogle Scholar
  19. 19.
    Rodriguez LM, Timmermans C, Wellens HJ: Are electrophysiological changes induced by longer lasting atrial fibrillation reversible? Observations using the atrial defibrillator. Circulation 1999, 100:113–116.PubMedGoogle Scholar
  20. 20.
    Haϊssaguerre M, Jaϊs P, Shah DC, et al.: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998, 339:659–666.CrossRefGoogle Scholar
  21. 21.
    Rohr S, Kucera JP, Kleber AG, et al.: Slow conduction in cardiac tissue, I: effects of a reduction of excitability versus a reduction of electrical coupling on microconduction. Circ Res 1998, 83:781–794.PubMedGoogle Scholar
  22. 22.
    Haϊssaguerre M, Jaϊs P, Shah DC, et al.: Catheter ablation of chronic atrial fibrillation targeting the reinitiating triggers. J Cardiovasc Electrophysiol 2000, 11:2–10.CrossRefGoogle Scholar
  23. 23.
    Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized trials. Arch Intern Med 1997, 157:1237–1240.CrossRefGoogle Scholar
  24. 24.
    Lundstrom T, Ryden L: Chronic atrial fibrillation: long-term results of direct current conversion. Acta Med Scand 1998, 223:53–59.CrossRefGoogle Scholar
  25. 25.
    Dethy M, Chassat C, Roy D, et al.: Doppler electrocardiographic predictors of recurrence of atrial fibrillation after cardioversion. Am J Cardiol 1988, 62:723–726.PubMedCrossRefGoogle Scholar
  26. 26.
    Roy D, Talajic M, Dorian P, et al.: Amiodarone to prevent recurrence of atrial fibrillation: Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000, 342:913–920. This large prospective trial demonstrated superiority of low-dose amiodarone over propafenone or sotalol in preventing recurrence of AF.PubMedCrossRefGoogle Scholar
  27. 27.
    The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group: Intravenous digoxin in acute atrial fibrillation: results of randomized, placebo-controlled multicenter trial in 239 patients. Eur Heart J 1997, 18:649–654.Google Scholar
  28. 28.
    Kuhlkamp V, Schirdewan A, Stangl K, et al.: Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cadiol 2000, 36:139–146.CrossRefGoogle Scholar
  29. 29.
    Chimienti M, Cullen MT, Casadei G, et al.: Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol 1996, 77:60A-65A.PubMedCrossRefGoogle Scholar
  30. 30.
    Southworth MR, Zarembski D, Viana M, et al.: Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. Am J Cardiol 1999, 83:1629–1632.PubMedCrossRefGoogle Scholar
  31. 31.
    Singh S, Zoble RG, Yellen L, et al.: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000, 102:2385–2390.PubMedGoogle Scholar
  32. 32.
    Greenbaum R, Campbell TJ, Channer KS, et al.: Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide: the EMERALD study [abstract]. Circulation 1998, 98:I-633.Google Scholar
  33. 33.
    Deedwania PC, Singh BN, Ellenbogen K, et al.: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observation for the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998, 98:2574–2579.PubMedGoogle Scholar
  34. 34.
    Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999, 341:857–865.PubMedCrossRefGoogle Scholar
  35. 35.
    Pappone C, Rosanio S, Oreto G, et al.: Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. Circulation 2000, 102:2619–2628.PubMedGoogle Scholar
  36. 36.
    Pappone C, Oreto G, Rosanio S, et al.: Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001, 104:2539–2544.PubMedGoogle Scholar
  37. 37.
    Gerstenfeld EP, Guerra P, Sparks PB, et al.: Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. J Cardiovasc Electrophysiol 2001, 12:900–908.PubMedCrossRefGoogle Scholar
  38. 38.
    Haϊssaguerre M, Jaϊs P, Shah DC, et al.: Electrophysiological end point for catheter ablation for atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000, 101:1409–1417.Google Scholar
  39. 39.
    Rawles JM: What is meant by a “controlled” ventricular rate in atrial fibrillation? Br Heart J 1990, 63:157–161.PubMedGoogle Scholar
  40. 40.
    Hohnloser SH, Kuck KH, Lilienthal J, et al.: Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet 2000, 356:1789–1794.PubMedCrossRefGoogle Scholar
  41. 41.
    Ven Gelder IC, Hagens VE, Bosker HA, et al.: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834–1840.PubMedCrossRefGoogle Scholar
  42. 42.
    The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825–1833. This is the largest prospective trial to compare rhythm control versus rate control in the management of patients with recurrent AF.CrossRefGoogle Scholar
  43. 43.
    Steinberg JS, Sadaniantz A, Miller J, et al.: Comparison of modes of death between randomized treatment strategies in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study [abstract]. PACE 2003, 26(Part II):184.Google Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • Parimal B. Maniar
    • 1
  • Jonathan S. Steinberg
    • 1
  1. 1.Division of CardiologySt. Luke’s-Roosevelt Hospital CenterNew YorkUSA

Personalised recommendations